- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04928469
Clinical Impact of COVID-19 by P.1 SARS-CoV-2 Lineage
Clinical Impact of Coronavirus Disease 19 (COVID-19) Caused by P.1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lineage
Since the first report of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) P.1 in Manaus, Brazil, a rapid spread of this lineage across the country has been observed. Recent studies indicate that this variant is associated with higher transmissibility; it is not known whether it is associated with clinical severity and higher mortality rates.
This is a retrospective cohort study carried out at Hospital de Clínicas de Porto Alegre. Adult patients aged 18 years or more and 65 years or less who were admitted to the hospital due to symptomatic COVID-19 from June 2020 to May 2021 and had a reverse transcriptase-polymerase chain reaction (RT-PCR) cycle threshold value for either SARS-CoV-2 N1 or N2 target ≤ 25 were eligible to the study. Samples from 86 patients (43 from June 2020 to November 2020 and 43 from February 2021 to May 2021) were sequenced for further evaluation. These dates were defined since the emergence of P.1 lineage in late January.
Clinical data regarding ventilatory support, date of onset of symptoms, laboratory findings and mortality were collected from each patient. This retrospective cohort aims to assess whether the number of days needed for supplementary oxygen either by noninvasive ventilation or high-flow nasal cannula from onset of symptoms differs among patients infected with the P.1 SARS-CoV-2 variant and those infected with other variants.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
RS
-
Porto Alegre, RS, Brasilien, 90035-903
- Hospital de Clínicas de Porto Alegre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients aged 18 to 65 years
- Hospital admission due to symptomatic COVID-19
- RT-PCR was collected from June to November 2020 or from February to May 2021
Exclusion Criteria:
- Patients admitted for reasons other than COVID-19
- Asymptomatic patients with positive routine screening with RT-PCR
- Patients transferred from other institutions
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
P.1
Patients infected with the P.1 SARS-CoV-2 variant
|
Collection of clinical and laboratory data
|
Other variants
Patients infected with SARS-CoV-2 variants other than P.1
|
Collection of clinical and laboratory data
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Time to Advanced Respiratory Support
Tidsramme: 28 days from onset of symptoms
|
Number of days needed for supplementary oxygen either by noninvasive ventilation or high-flow nasal cannula from onset of symptoms.
|
28 days from onset of symptoms
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Proportion of patients in each category in the ordinal scale during hospitalization
Tidsramme: 28 days from hospital admission
|
Proportion of patients in each category in the ordinal scale during hospitalization.
Ordinal scale levels: 1, patient not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation or extracorporeal membrane oxygenation; and 6, death.
|
28 days from hospital admission
|
Arterial oxygen partial pressure (PaO2)/ Fractional inspired oxygen (FiO2) evolution during hospitalization
Tidsramme: 28 day from hospital admission
|
Proportion of patients in each category according to PaO2/FiO2 value: 400-301, 300-201, 200-101, <=100.
|
28 day from hospital admission
|
28-day Mortality from onset of symptoms
Tidsramme: 28 days from onset of symptoms
|
Death for any cause from onset of symptoms
|
28 days from onset of symptoms
|
Time to death from onset of symptoms
Tidsramme: 28 days from onset of symptoms
|
Number of days from the onset of symptoms to death
|
28 days from onset of symptoms
|
28-day Mortality from hospital admission
Tidsramme: 28 days from hospital admission
|
Death for any cause from hospital admission
|
28 days from hospital admission
|
Time to death from hospital admission
Tidsramme: 28 days from hospital admission
|
Number of days from the hospital admission to death
|
28 days from hospital admission
|
Days alive and free of supplemental oxygen support.
Tidsramme: 28 day from hospital admission
|
Number of days alive and free of supplemental oxygen support
|
28 day from hospital admission
|
Time to invasive ventilatory support
Tidsramme: 28 days from onset of symptoms
|
Number of days from the onset of symptoms to mechanical ventilation or Extracorporeal membrane oxygenation (ECMO)
|
28 days from onset of symptoms
|
Need of critical care
Tidsramme: 28 days from hospital admission
|
Proportion of patients admitted to Intensive Care Unit
|
28 days from hospital admission
|
In-hospital mortality
Tidsramme: 90 days from hospital admission
|
Death for any cause during hospitalization
|
90 days from hospital admission
|
Number of thromboembolic event
Tidsramme: 28 day from hospital admission
|
Number of patients with documented deep venous thrombosis or pulmonary embolism
|
28 day from hospital admission
|
Number of patients requiring renal replacement therapy (RRT)
Tidsramme: 28 day from hospital admission
|
Number of patients requiring any form of RRT during hospitalization
|
28 day from hospital admission
|
Number of patients requiring prone positioning
Tidsramme: 28 day from hospital admission
|
Number of patients requiring prone positioning during hospitalization
|
28 day from hospital admission
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2020-0163
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Studiedata/dokumenter
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Covid19
-
Anavasi DiagnosticsIkke rekrutterer endnu
-
Ain Shams UniversityRekruttering
-
Israel Institute for Biological Research (IIBR)Afsluttet
-
Colgate PalmoliveAfsluttet
-
Christian von BuchwaldAfsluttet
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdAktiv, ikke rekrutterende
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichTilmelding efter invitation
-
Alexandria UniversityAfsluttet
-
Henry Ford Health SystemAfsluttet
Kliniske forsøg med No intervention performed
-
Otsuka Pharmaceutical Factory, Inc.CelerionAfsluttet
-
Seoul National University HospitalSamsung Medical Center; Chosun University HospitalAfsluttetRadiofrekvensablation | Mikrobølge-ablationKorea, Republikken
-
University of MinnesotaAfsluttet
-
Swiss Federal Institute of TechnologyInstituto de Investigação em ImunologiaAfsluttetForstyrrelser i jernmetabolisme | Overbelastning af jern | PolyfenolerPortugal, Schweiz
-
Catharina Ziekenhuis EindhovenAfsluttet
-
Assistance Publique - Hôpitaux de ParisAfsluttetSeglcellesygdomFrankrig
-
China National Center for Cardiovascular DiseasesUkendt
-
Northwestern UniversityAfsluttet
-
University of Sao Paulo General HospitalUkendtParkinsons sygdomBrasilien